Free tool
FAERS Monitor: Movantik
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204760 or its brand name (Movantik, Naloxegol Oxalate). Reports on generic versions are filed under their own applications.
Reports
3,970
Serious
1,878
47% of reports
Hospitalization
908
Death reported
288
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea386
- constipation384
- drug ineffective377
- pain367
- nausea332
- off label use275
- abdominal pain264
- abdominal pain upper229
- intentional product misuse224
- vomiting210
- death188
- fatigue187
- headache187
- hyperhidrosis185
- malaise176
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 2 |
| 2015 | 371 |
| 2016 | 675 |
| 2017 | 575 |
| 2018 | 352 |
| 2019 | 300 |
| 2020 | 254 |
| 2021 | 263 |
| 2022 | 235 |
| 2023 | 235 |
| 2024 | 254 |
| 2025 | 271 |
| 2026 | 174 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,189 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intentional product misuseSignal | 224 | 13.6 | 12.0 | 2,604 |
| constipationSignal | 384 | 9.3 | 8.5 | 2,877 |
| hyperhidrosisSignal | 185 | 7.6 | 6.6 | 1,062 |
| abdominal painSignal | 264 | 6.0 | 5.4 | 1,111 |
| abdominal pain upperSignal | 229 | 5.9 | 5.2 | 935 |
| diarrhoeaSignal | 386 | 3.2 | 2.9 | 589 |
| painSignal | 367 | 3.2 | 2.9 | 558 |
| vomitingSignal | 210 | 2.4 | 2.1 | 168 |
| nauseaSignal | 332 | 2.2 | 2.0 | 231 |
| malaiseSignal | 176 | 2.1 | 1.8 | 106 |
| off label use | 275 | 1.7 | 1.5 | 75 |
| headache | 187 | 1.6 | 1.4 | 40 |
| drug ineffective | 377 | 1.5 | 1.4 | 70 |
| fatigue | 187 | 1.3 | 1.1 | 11 |
| death | 188 | 1.2 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.